Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

NP-C Therapeutics

NP-C Therapeutics
Out of Business LATEST DEAL TYPE

Developer of a treatment therapy designed to treat Niemann-Pick Type C. The company's treatment therapy uses combination of three drugs which help to treat lysosomal storage diseases, enabling patients to recover severe liver disease from infiltration of the liver and respiratory failure from infiltration of the lungs.

Ownership Status
Out of Business
Financing Status
Formerly Angel backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 650 Park Avenue
  • Suite 20
  • King of Prussia, PA 19406
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore NP-C Therapeutics’s full profile, request a free trial.

NP-C Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Jun-2017 00000 Completed Out of Business
1. Angel (individual) 01-Apr-2016 00000 00000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

NP-C Therapeutics Executive Team (3)

Name Title Board
Kasturi Haldar Ph.D Chief Scientific Officer
William Claypool MD President, Board Member & Chief Executive Officer
Dennis Willson Chairman

NP-C Therapeutics Board Members (1)

Name Representing Role Since Contact
Dennis Willson Self Chairman 000 0000